Analysts expect Valneva to post earnings of ($0.22) per share and revenue of $55.64 million for the quarter. Valneva Trading Up 0.1 % NASDAQ VALN opened at $6.80 on Monday.

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 - ...

Saint-Herblain (France), March 3, 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming investor ...

VALNEVA Declaration of shares and voting rights February 28, 2025_____ Company name: VALNEVARegistered office ...

Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics. The French pharma company ...

[{"search_type":"general-inventory-search","vehicle_array":[{"trim":"3.6 V6 SE w/ Technology","make":"Volkswagen","cat":"crossover_midsize","year":"2021","customer_id ...

New data for Valneva and Pfizer's experimental vaccine for Lyme disease – the furthest ahead in clinical testing – have bolstered the case for the shot as the results of a phase 3 programme ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

GLUE Monte Rosa Therapeutics, Inc.